Agilent Technologies, Inc. (0HAV.L)
USD 108.54
(1.45%)
USD 108.54
(1.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.67 Billion USD | -10.5% |
| 2022 | 1.9 Billion USD | 8.12% |
| 2021 | 1.72 Billion USD | 43.49% |
| 2020 | 1.22 Billion USD | -0.24% |
| 2019 | 1.23 Billion USD | 0.0% |
| 2018 | 1.23 Billion USD | 12.52% |
| 2017 | 1.06 Billion USD | 26.91% |
| 2016 | 863 Million USD | 7.88% |
| 2015 | 778 Million USD | -30.04% |
| 2014 | 831 Million USD | -14.65% |
| 2013 | 1.34 Billion USD | -6.37% |
| 2012 | 1.45 Billion USD | 6.8% |
| 2011 | 1.39 Billion USD | 69.8% |
| 2010 | 1 Billion USD | 231.09% |
| 2009 | 47 Million USD | -75.36% |
| 2008 | 1.13 Billion USD | 25.45% |
| 2007 | 952 Million USD | 68.86% |
| 2006 | 899 Million USD | 55.1% |
| 2005 | 508 Million USD | -52.88% |
| 2004 | 624 Million USD | 256.78% |
| 2003 | -398 Million USD | 57.3% |
| 2002 | -932 Million USD | -170.14% |
| 2001 | -345 Million USD | -124.01% |
| 2000 | 1.43 Billion USD | 22.82% |
| 1999 | 1.17 Billion USD | 27.31% |
| 1998 | 919 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 426 Million USD | -5.63% |
| 2024 Q3 | 457 Million USD | 4.82% |
| 2024 Q1 | 462 Million USD | -8.15% |
| 2023 FY | - USD | -10.5% |
| 2023 Q3 | 227 Million USD | -51.91% |
| 2023 Q1 | 502 Million USD | -8.89% |
| 2023 Q2 | 472 Million USD | -5.98% |
| 2023 Q4 | 504 Million USD | 122.03% |
| 2022 Q1 | 422 Million USD | -23.69% |
| 2022 Q3 | 496 Million USD | 13.76% |
| 2022 FY | - USD | 8.12% |
| 2022 Q4 | 551 Million USD | 11.09% |
| 2022 Q2 | 436 Million USD | 3.32% |
| 2021 Q4 | 553 Million USD | 28.01% |
| 2021 Q1 | 407 Million USD | 7.67% |
| 2021 Q2 | 370 Million USD | -9.09% |
| 2021 Q3 | 432 Million USD | 16.76% |
| 2021 FY | - USD | 43.49% |
| 2020 Q2 | 217 Million USD | -31.76% |
| 2020 Q4 | 378 Million USD | 20.0% |
| 2020 FY | - USD | -0.24% |
| 2020 Q3 | 315 Million USD | 45.16% |
| 2020 Q1 | 318 Million USD | -3.05% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | 328 Million USD | 11.19% |
| 2019 Q3 | 295 Million USD | 2.43% |
| 2019 Q2 | 288 Million USD | -10.0% |
| 2019 Q1 | 320 Million USD | 0.63% |
| 2018 Q4 | 318 Million USD | 1.6% |
| 2018 Q1 | 304 Million USD | 2.01% |
| 2018 Q3 | 313 Million USD | 5.74% |
| 2018 Q2 | 296 Million USD | -2.63% |
| 2018 FY | - USD | 12.52% |
| 2017 Q1 | 268 Million USD | 18.58% |
| 2017 Q4 | 298 Million USD | 13.31% |
| 2017 Q3 | 263 Million USD | -0.75% |
| 2017 FY | - USD | 26.91% |
| 2017 Q2 | 265 Million USD | -1.12% |
| 2016 FY | - USD | 7.88% |
| 2016 Q4 | 226 Million USD | 7.11% |
| 2016 Q2 | 199 Million USD | -11.95% |
| 2016 Q1 | 226 Million USD | 3.2% |
| 2016 Q3 | 211 Million USD | 6.03% |
| 2015 Q4 | 219 Million USD | 5.8% |
| 2015 Q2 | 176 Million USD | -10.66% |
| 2015 Q1 | 197 Million USD | -2.96% |
| 2015 FY | - USD | -30.04% |
| 2015 Q3 | 207 Million USD | 17.61% |
| 2014 FY | - USD | -14.65% |
| 2014 Q3 | 310 Million USD | -0.96% |
| 2014 Q4 | 203 Million USD | -34.52% |
| 2014 Q1 | 316 Million USD | -16.62% |
| 2014 Q2 | 313 Million USD | -0.95% |
| 2013 FY | - USD | -6.37% |
| 2013 Q2 | 315 Million USD | 0.32% |
| 2013 Q3 | 330 Million USD | 4.76% |
| 2013 Q4 | 379 Million USD | 14.85% |
| 2013 Q1 | 314 Million USD | -16.04% |
| 2012 FY | - USD | 6.8% |
| 2012 Q4 | 374 Million USD | 37.5% |
| 2012 Q3 | 272 Million USD | -9.93% |
| 2012 Q2 | 302 Million USD | -10.12% |
| 2012 Q1 | 336 Million USD | -11.58% |
| 2011 FY | - USD | 69.8% |
| 2011 Q3 | 347 Million USD | 4.2% |
| 2011 Q1 | 278 Million USD | -1.07% |
| 2011 Q2 | 333 Million USD | 19.78% |
| 2011 Q4 | 380 Million USD | 9.51% |
| 2010 Q4 | 281 Million USD | 57.87% |
| 2010 Q3 | 178 Million USD | -7.77% |
| 2010 Q2 | 193 Million USD | 40.88% |
| 2010 FY | - USD | 231.09% |
| 2010 Q1 | 137 Million USD | 19.13% |
| 2009 Q4 | 115 Million USD | 155.56% |
| 2009 FY | - USD | -75.36% |
| 2009 Q1 | 53 Million USD | -81.21% |
| 2009 Q2 | -1 Million USD | -101.89% |
| 2009 Q3 | 45 Million USD | 4600.0% |
| 2008 FY | - USD | 25.45% |
| 2008 Q1 | 179 Million USD | -25.42% |
| 2008 Q3 | 270 Million USD | 14.89% |
| 2008 Q2 | 235 Million USD | 31.28% |
| 2008 Q4 | 282 Million USD | 4.44% |
| 2007 Q2 | 175 Million USD | 25.0% |
| 2007 Q4 | 240 Million USD | 11.63% |
| 2007 Q3 | 215 Million USD | 22.86% |
| 2007 Q1 | 140 Million USD | -35.78% |
| 2007 FY | - USD | 68.86% |
| 2006 Q2 | 57 Million USD | 50.0% |
| 2006 Q3 | 143 Million USD | 150.88% |
| 2006 Q4 | 218 Million USD | 52.45% |
| 2006 FY | - USD | 55.1% |
| 2006 Q1 | 38 Million USD | 174.51% |
| 2005 Q3 | 113 Million USD | 9.71% |
| 2005 Q4 | -51 Million USD | -145.13% |
| 2005 FY | - USD | -52.88% |
| 2005 Q1 | 129 Million USD | -12.84% |
| 2005 Q2 | 103 Million USD | -20.16% |
| 2004 Q4 | 148 Million USD | -1.99% |
| 2004 Q3 | 151 Million USD | -10.65% |
| 2004 Q1 | 156 Million USD | 25.81% |
| 2004 FY | - USD | 256.78% |
| 2004 Q2 | 169 Million USD | 8.33% |
| 2003 Q1 | -178 Million USD | 16.43% |
| 2003 FY | - USD | 57.3% |
| 2003 Q4 | 124 Million USD | 226.53% |
| 2003 Q3 | -98 Million USD | 60.16% |
| 2003 Q2 | -246 Million USD | -38.2% |
| 2002 FY | - USD | -170.14% |
| 2002 Q4 | -213 Million USD | 16.47% |
| 2002 Q3 | -255 Million USD | -26.24% |
| 2002 Q2 | -202 Million USD | 22.9% |
| 2002 Q1 | -262 Million USD | 36.71% |
| 2001 Q1 | 399 Million USD | -33.28% |
| 2001 Q4 | -414 Million USD | -128.73% |
| 2001 Q3 | -181 Million USD | -16.03% |
| 2001 Q2 | -156 Million USD | -139.1% |
| 2001 FY | - USD | -124.01% |
| 2000 Q3 | 328 Million USD | 19.27% |
| 2000 Q1 | 236 Million USD | 104.59% |
| 2000 FY | - USD | 22.82% |
| 2000 Q2 | 275 Million USD | 16.53% |
| 2000 Q4 | 598 Million USD | 82.32% |
| 1999 Q4 | -5.14 Billion USD | -346.38% |
| 1999 Q3 | 2.08 Billion USD | 3.83% |
| 1999 FY | - USD | 27.31% |
| 1999 Q2 | 2.01 Billion USD | 12.54% |
| 1999 Q1 | 1.78 Billion USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 762.584% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 3416.064% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 2006.007% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 585.433% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 730.458% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 1525.414% |
| Imunon, Inc. | -20.78 Million USD | 8169.376% |
| Dynavax Technologies Corporation | 9.66 Million USD | -17249.472% |
| Editas Medicine, Inc. | -163.11 Million USD | 1128.096% |
| FibroGen, Inc. | -261.4 Million USD | 741.533% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 473.486% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 4747.747% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -303.028% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 481.834% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -1606.662% |
| Verastem, Inc. | -83.16 Million USD | 2116.449% |
| Zoetis Inc. | 3.68 Billion USD | 54.491% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 63.585% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 2018.172% |
| Homology Medicines, Inc. | -47.75 Million USD | 3611.601% |
| Nektar Therapeutics | -243.1 Million USD | 789.82% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1763.245% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 4598.029% |
| Perrigo Company plc | 646.2 Million USD | -159.517% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 1217.196% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 114.87% |
| Illumina, Inc. | -608 Million USD | 375.822% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 84.472% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 48.495% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 1715.731% |
| Waters Corporation | 1.02 Billion USD | -64.05% |
| Biogen Inc. | 2.37 Billion USD | 29.449% |
| Evolus, Inc. | -41.81 Million USD | 4111.002% |
| Adicet Bio, Inc. | -136.53 Million USD | 1328.256% |
| bluebird bio, Inc. | -167.16 Million USD | 1103.224% |
| Geron Corporation | -174.78 Million USD | 1059.481% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 835.136% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 1921.262% |
| Myriad Genetics, Inc. | -67.8 Million USD | 2573.451% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 431.217% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | -44.066% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 3873.908% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -440.473% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 63.968% |
| OPKO Health, Inc. | -65.51 Million USD | 2659.68% |
| Exelixis, Inc. | 196.6 Million USD | -752.992% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -1448.133% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 3107.748% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 845.363% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 829.099% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -271.061% |
| Blueprint Medicines Corporation | -474.61 Million USD | 453.341% |
| Insmed Incorporated | -654.73 Million USD | 356.133% |
| TG Therapeutics, Inc. | 26.1 Million USD | -6325.287% |
| Incyte Corporation | 919.42 Million USD | -82.396% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 431.882% |